Facing mounting financial pressures, insurance companies are changing the prescription drug coverage available to many consumers in Medicare Part D.
Inflation Reduction Act
Posted inCost of Care
Can Medicare Afford to Foot the Bill for New Alzheimer’s Drugs?
Recent analyses in JAMA and by the Kaiser Family Foundation raise questions about whether Medicare and its beneficiaries can afford a new wave of Alzheimer’s treatments.
Posted inCost of Care
Medicare Director Meena Seshamani on CMS’ New Drug Pricing Powers
Medicare director Meena Seshamani discusses her team’s sprint to put historic drug price reforms into action.
Posted inPublic Health
Three Health Policy Stories to Watch in 2023
In 2023, states will pursue new abortion laws, restart Medicaid eligibility checks and Medicare will begin to flex its new power to negotiate drug prices.
Posted inPublic Health
Drugmakers and Patient Assistance Programs: Tricks or Treats?
Stacie Dusetzina shares new research that examines the link between drug companies’ charity donations and their business incentives.
Posted inInsurance
Medicare’s Prescription Drug Plan Makeover
An overhaul of Medicare’s prescription drug benefit will lower costs for seniors while changing incentives for insurers and drugmakers.
Posted inInsurance
4 Studies that Explain the Stakes of Medicare Open Enrollment
Leslie Walker shares four research studies to explain the stakes of Medicare open enrollment.
Posted inCost of Care
The Race to Prepare for Medicare’s New Drug Pricing Powers
Congress gave Medicare historic new powers to lower drug prices, but lawsuits, loopholes and opposition from the drug industry could undermine them.
Posted inCost of Care
Dems’ New Drug Pricing Deal: What You Need to Know
Stacie Dusetzina shares key takeaways from the drug pricing provisions of the new Inflation Reduction Act.